Mayo Clinic Backs Virtual Biomarker Startup $4.9M

A Game-Changing Investment in AI-Driven Diagnostics

Source: DistilINFO

Mayo Clinic has joined a $4.9 million seed funding round for ViewsML, an emerging healthcare technology startup building what it describes as the world’s first virtual biomarker library. Wittington Ventures led the round. Together, these two backers are placing a significant bet on a new approach to pathology — one that could reshape how clinicians detect disease and personalize treatment.

This investment signals a broader shift in how top-tier health systems view artificial intelligence. Rather than simply adopting AI tools, institutions like Mayo Clinic now actively fund the companies building them.

What Is ViewsML and Why It Matters

Building the First Virtual Biomarker Library

ViewsML is developing a first-of-its-kind platform that uses AI to extract diagnostic insights directly from standard pathology images. Traditionally, biomarker testing requires separate, often expensive laboratory procedures. ViewsML changes that model entirely.

Instead of running additional lab tests, the platform analyzes existing tissue slide images and identifies biomarkers virtually. This approach eliminates redundant steps, reduces cost, and speeds up the diagnostic process. Furthermore, it opens the door to identifying markers that conventional staining methods might miss altogether.

Read the full article from DistillINFO here.